On Tuesday, Microvision, Inc. (NASDAQ:MVIS)’s shares declined -9.48% to $2.96.
Microvision, Inc. (MVIS) declared it entered into a $6 million At-the-Market (ATM) equity offering agreement with Meyers Associates, L.P. (doing business as BP Capital, a division of Meyers Associates, L.P.), or BP Capital, on May 5, 2015.
Under the agreement MicroVision may, from time to time, at its discretion offer and sell shares of its common stock having an aggregate value of up to $6 million through BP Capital. MicroVision intends to use the net proceeds from this facility, if any, for general corporate purposes, which may comprise, but are not limited to, working capital, capital expenditures and acquisitions of other technologies.
MicroVision, Inc. engages in the development of PicoP display technology that can be used by its customers to create miniature laser display and imaging engines in the United States.
Digital Ally, Inc. (NASDAQ:DGLY)’s shares dropped -9.46% to $16.36.
Digital Ally, Inc. (DGLY) declared that it will be presenting at the 16th Annual B. Riley & Co. Investor Conference on Tuesday, May 12, 2015. The conference is being held May 12-14, 2015 at the Loews Hollywood Hotel, which is located at 1755 N. Highland Avenue in Hollywood, California.
Digital Ally, Inc. produces digital video imaging and storage products for use in law enforcement, security, and commercial applications in the United States and internationally.
At the end of Tuesday’s trade, Array Biopharma Inc (NASDAQ:ARRY)‘s shares dipped -8.05% to $6.57.
Array Biopharma Inc (ARRY) reported results for the third quarter of its fiscal year ending June 30, 2015.
Array ended the quarter with $191 million in cash, cash equivalents and marketable securities. Revenue for the third quarter of fiscal 2015 was $6.6 million, contrast to $7.8 million for the same period last year. Cost of partnered programs for the third quarter of fiscal 2015 was $12.1 million, contrast to $10.8 million for the same period last year. Research and development expense was $11.8 million, contrast to $14.1 million in the same preceding year period. Net income for the third quarter was $58.3 million, or $0.37 per share (diluted), contrast to a net loss of $24.9 million, or ($0.20) per share (diluted), for the same period in fiscal 2014. As part of the Novartis transaction, Array received an $85 million cash payment and extinguished net liabilities of $21.6 million which resulted in an enhance in working capital of $106.6 million.
Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific.
Zendesk Inc (NYSE:ZEN), ended its Tuesday’s trading session with -7.80% loss, and closed at $20.57.
Zendesk Inc (ZEN) stated financial results for the fiscal quarter ended March 31, 2015.
Results for the First Quarter 2015
Revenue was $42.2 million for the quarter ended March 31, 2015, an enhance of 68% over the preceding year period. GAAP net loss for the quarter ended March 31, 2015 was $19.2 million, and GAAP net loss per share was $0.25. Non-GAAP net loss was $7.8 million, and non-GAAP net loss per share was $0.10. Non-GAAP net loss excludes about $10.9 million in share-based compensation related expenses (counting $0.2 million of amortized share-based compensation capitalized in internal-use software and $0.5 million of employer tax related to employee stock transactions) and $0.4 million of amortization of purchased intangibles. GAAP and non-GAAP net loss per share for the quarter ended March 31, 2015 were based on 76.3 million weighted average shares outstanding.
Zendesk, Inc., a software development company, provides software as a service customer service platform for organizations. It provides single customer service interface to organizations to manage all their one-on-one customer interactions; track and predict common questions; and provide a seamless path to answers.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
